Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A series of hybrid compounds based on natural products-bile acids and dihydroartemisinin-were prepared by different synthetic methodologies and investigated for their in vitro biological activity against HL-60 leukemia and HepG2 hepatocellular carcinoma cell lines. Most of these hybrids presented significantly improved antiproliferative activities with respect to dihydroartemisinin and the parent bile acid. The two most potent hybrids of the series exhibited a 10.5- and 15.4-fold increase in cytotoxic activity respect to dihydroartemisinin alone in HL-60 and HepG2 cells, respectively. Strong evidence that an ursodeoxycholic acid hybrid induced apoptosis was obtained by flow cytometric analysis and western blot analysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cmdc.201800756 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-drug interaction between dolutegravir and artemether-lumefantrine in HIV and malaria mono- and co-infections: a pharmacogenetic analysis from Ghana.
AIDS Res Ther
August 2025
Medical and Scientific Research Centre, University of Ghana Medical Centre, Legon, Accra, Ghana.
Background: Human Immunodeficiency Virus and malaria are significant public health challenges in sub-Saharan Africa, contributing substantially to morbidity and mortality in the region. The trajectory of HIV and malaria mono- and coinfections may be different with presentations of drug-drug and disease-disease interactions. Current medications of artemether-lumefantrine and dolutegravir (DTG) -based anti-retroviral therapy which are the preferred drugs are metabolised by CYP2B6, CYP3A4/5 and UGTs which are polymorphic and may contribute to drug disposition and clinical outcomes.
View Article and Find Full Text PDFPrevalence of Plasmodium falciparum plasmepsin2/3 gene duplication in Africa and Asia: a systematic review and meta-analysis.
Malar J
August 2025
Department of Biochemistry, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Background: The Plasmodium falciparum delayed clearance phenotype due to the emergence of partial artemisinin resistance has been documented in Asia and Africa, where it is associated with treatment failure of artemisinin-based combination therapy (ACT). The amplification of the Plasmodium falciparum plasmepsin2/3 gene (pfpm2/3) has been shown to decrease the susceptibility of P. falciparum to piperaquine, leading to treatment failure among patients on dihydroartemisinin-piperaquine.
View Article and Find Full Text PDFFrequencies of molecular markers of drug resistance in the context of two different Seasonal Malaria Chemoprevention (SMC) treatment regimens in the Koulikoro health district, Mali.
Antimicrob Agents Chemother
August 2025
University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
With growing concern about parasite resistance to sulfadoxine-pyrimethamine (SP) in West Africa, the effectiveness of dihydroartemisinin-piperaquine (DHA + PQ) was assessed as an alternative drug regimen for Seasonal Malaria Chemoprevention (SMC). This study aims to determine the prevalence of molecular markers of resistance to SP + AQ and DHA + PQ in Koulikoro (Mali), where SMC has been implemented since 2014. -positive samples were analyzed by either next-generation sequencing, focusing on SNPs in genes known to be associated with resistance: and genes, and using qPCR for copy number variations (CNVs) of and .
View Article and Find Full Text PDFOvercoming venetoclax resistance through heme-mediated NOXA/cyclin D1/Mcl-1 axis with a novel artemisinin conjugate.
Blood Adv
August 2025
Shenyang Pharmaceutical University, Shenyang, China.
The Bcl-2 inhibitor venetoclax remains the sole apoptosis-inducing agent approved for combination therapy in elderly patients with acute myeloid leukemia (AML). However, its clinical efficacy is frequently constrained by the emergence of drug resistance, which involves the overexpression or induction of Mcl-1 and Bcl-xL proteins. To address this challenge, we developed a novel strategy to enhance venetoclax activity and overcome resistance by producing NOXA through the conjugation of dihydroartemisinin (DHA) to venetoclax using a chemical synthesis approach.
View Article and Find Full Text PDFCan hair concentrations of artemether-lumefantrine be used as a tool to retrospectively determine drug exposure during malaria treatment?
New Microbes New Infect
October 2025
Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, Location University of Amsterdam, Amsterdam, Netherlands.
Background: Artemether-lumefantrine (AL) is the first-line treatment for uncomplicated malaria, with cure rates exceeding 95 %. However, recrudescence occurs in 2-14 % of cases, often linked to inadequate lumefantrine exposure. Retrospective assessment of drug exposure in recrudescence cases is challenging, as lumefantrine levels are undetectable in blood after several weeks.
View Article and Find Full Text PDF